Day 1 Highlights from ASH 2024: Breakthroughs in Sickle Cell Disease and ITP

Day 1 of ASH 2024 brought exciting advancements in hematology. In this episode, we explore highlights from pivotal trials, including etavopivat’s impact on sickle cell disease, rilzabrutinib’s rapid platelet response in ITP, and hydroxyurea’s benefits for HbSC patients. Hosted by Matt, this podcast offers clear insights into the research shaping tomorrow’s treatments.

Love what you hear? Download the Curie app for daily updates and bonus episodes tailored for oncology professionals.